Institute of Good Manufacturing Practices India

Global accredited training & certification provider

IGMPI Approvals & Accreditation : Approved by Quality Council of India (QCI) & Accredited Vocational Institution of Ministry of HRD, Government of India, Approved Training Institute of Food Safety and Standards Authority of India (FSSAI), Recognized by Department of Industrial Policy & Promotion, Ministry of Commerce & Industry, Government of India, An ISO 9001:2015 Certified Organisation registered under The Societies Registration Act,1860 Government of India Empanelled under Ministry of Horticulture and Food Processing, Government of Uttar Pradesh, Affiliated with Life Sciences and Food Industry Sector Skills Council (SSC)
Trusted by organizations & training participants in over 30 countries. Training | Certification | Education | Research

Novartis Cosentyx® showed efficacy in psoriatic arthritis manifestations

12th June 2019

Rheumatology and immune-dermatology leader, Novartis announced new clinical data from MAXIMISE trial evaluating the efficacy and safety of Cosentyx (secukinumab) in the management of axial manifestations of psoriatic arthritis (PsA).

PsA is a complex disease with multiple manifestations, closely associated with psoriasis. It is part of the inflammatory disease family (spondyloarthritis) which affects up to 50 million people worldwide.

MAXIMISE is a 52-week, double-blind, randomized, placebo-controlled Phase Ⅲb study to evaluate the efficacy and safety of Cosentyx (secukinumab) in the management of PsA axial manifestations. 498 patients with PsA were enrolled in the trial. It met both its primary and secondary endpoint with 63.1% of Cosentyx 300 mg and 66.3% of Cosentyx 150 mg achieving ASAS20 at week 12 (versus 31.3% for placebo). Rapid onset of relief was seen in patients as early as week four.

Cosentyx is first and only fully human biologic that inhibits interleukin-17A, a cornerstone cytokine which cause inflammation and development of PsA, psoriasis and ankylosing spondylitis. Used by 200,000 patients worldwide since used and its safety is backed by robust clinical data. Cosentyx bridges for the first-time treatment of psoriasis, psoriatic arthritis and axial manifestations.

For further enquiries, write to or call us on: +91 8587838177, +91 8130924488, 0120-2427175, 0120-4375280

Pharmaceuticals | Food | Clinical Research | Healthcare | Medical Coding | Medical Device | Nanotechnology | IPR

Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like